171P Pharmacodynamic (PD) biomarker analysis from CheckMate (CM) 8KX: A multitumor study of a subcutaneous (SC) formulation of nivolumab (NIVO) monotherapy. (December 2022) - Jackson, C.G.C.A.; Perumal, D.; Lugowska, I.; O'Donnell, A.; North, R.T.; Calvo Ferrandiz, P.A.; Latten-Jansen, L.M.; Sánchez, C.G.; Medina Rodríguez, L.M.; Santoro, A.; Li, L.; Sidik, K.; et al.